阿立哌唑与利培酮治疗首发精神分裂症患者疗效的对照研究  

The Clinical Study on Aripiprazole and Risperidone in Treatment of First-onset Schizophrenia.

作　　者：冯砚国[1] 阎喜英[1] 赵峥[1] 王东平[1] 王世贵[1] 李予春[1] 王云[1] 

机构地区：[1]中国.新乡医学院第二附属医院精神一科,453002

出　　处：《中国健康心理学杂志》2006年第4期418-419,共2页China Journal of Health Psychology

摘　　要：目的探讨阿立哌唑治疗精神分裂症患者的疗效及安全性。方法将符合CCM D-3、ICD-10诊断标准60例的精神分裂症患者进行8周的临床观察,用PAN SS、CG I、TESS、体格检查及实验检查评定疗效和安全性。结果阿立哌唑和利培酮用量分别为22.68±4.91m g/日、3.94±1.43m g/日。实验组和对照组的有效率分别为73.33%和76.67%,治愈率分别为53.33%和50.00%;两组患者PAN SS量表总分治疗后2、4、6、8周与治疗前比较差异有显著性(P<0.01),两组之间比较(P>0.05);PAN SS量表阳性症状及一般精神病理症状因子治疗后各周与治疗前比较差异有显著性(P<0.05)。结论阿立哌唑对精神症状全面有效,在改善阴性症状方面起效较快,不良反应轻微,是一种安全、有效的新型抗精神病药物。Objective To explore the clinical efficacy and safety between Aripiprazole and Risperidone in the treatment of first-onset schizophrenia. Methods 60 patients who met CCMD- 3 and ICD- 10 for were randomly divided into two groups： one group was treated with Aripiprazole （Test group） and the other group with Risperldone （control group） for 8 weeks. The PANSS, CGI, TESS and physical and experiment laboratory examination were used to measure clinical efficacy and side effects. Results The dosage of Aripiprazole was 22.68±4.91mg per day, and Risperidone 3.94±1.43rag per day. Total clinical effective rate was 73, 33% in Aripiprazole group and 76.19% in Risperidone group. The cure rate were 53. 33% and 50.00% respectively. The PANSS scores in two groups decreased significantly after treatment in every week （P〈0. 01）, but there were no significant defference between two groups （P〈0.05）. Conclusion Aripiprazole is effective and safety drugs in the teratment of first-onset schizophrenia.

关 键 词：精神分裂症 阿立哌唑 利培酮 疗效 安全性 

分 类 号：R971.4[医药卫生—药品] R581.1[医药卫生—药学]